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The intracellular generation of reactive oxygen spe-
cies, together with the thioredoxin and glutathione sys-
tems, is thought to participate in redox signaling in
mammalian cells. The activity of thioredoxin is depend-
ent on the redox status of thioredoxin reductase (TR),
the activity of which in turn is dependent on a seleno-
cysteine residue. Two mammalian TR isozymes (TR2
and TR3), in addition to that previously characterized
(TR1), have now been identified in humans and mice. All
three TR isozymes contain a selenocysteine residue that
is located in the penultimate position at the carboxyl
terminus and which is encoded by a UGA codon. The
generation of reactive oxygen species in a human carci-
noma cell line was shown to result in both the oxidation
of the selenocysteine in TR1 and a subsequent increase
in the expression of this enzyme. These observations
identify the carboxyl-terminal selenocysteine of TR1
as a cellular redox sensor and support an essential role
for mammalian TR isozymes in redox-regulated cell
signaling.
Reactive oxygen species (ROS),1 such as hydrogen peroxide,
the superoxide anion radical, and the hydroxyl radical, have
been thought of as toxic by-products of cellular oxygen metab-
olism. Excessive production of ROS or an insufficiency of anti-
oxidant defenses has been implicated in apoptosis, aging, and
cancer (1). However, recent evidence indicates that, at low
concentrations, ROS mediate regulatory events and are essen-
tial participants in cell signaling (2). Redox signaling is
thought to be achieved through the coupling of ROS with oxi-
dation-reduction processes that involve essential thiol groups
in proteins, resulting in the modulation of tyrosine or serine-
threonine phosphorylation of target proteins (3, 4). The redox
state of essential thiol groups is controlled by two cellular redox
systems: the thioredoxin (thioredoxin, thioredoxin reductase
(designated TR herein, but it should be noted that TrxR has
also been used, e.g. see Ref. 5–8), and thioredoxin peroxidase)
and glutathione (glutathione, glutathione reductase, glutare-
doxin, and glutathione peroxidase (GPX)) systems (9). Al-
though the role of ROS in intracellular signaling has been
demonstrated (2, 10), the direct targets of these molecules
remain poorly characterized, and the specific mechanisms
through which ROS are sensed within mammalian cells are
unclear (3, 4, 11).
Several proteins, including apoptosis signal-regulating ki-
nase 1 (ASK1; this protein belongs to a family of mitogen-
activated protein kinase kinase kinases) (12), protein-tyrosine
phosphatase 1B (PTP1B) (13), and thioredoxin peroxidase (14),
have been identified as components of redox signaling path-
ways that act downstream of the generation of intracellular
ROS. The activities of these proteins are regulated by thiore-
doxin; reduced thioredoxin activates the phosphatase and per-
oxidase, and inactivates the kinase (12–14). Thioredoxin is a
12-kDa protein that catalyzes the reduction of protein disul-
fides and regulates a variety of processes including reduction of
ribonucleotide reductase, protein-DNA interactions, and cellu-
lar growth (9). The redox state and activity of thioredoxin are in
turn controlled by TR, a selenocysteine-containing flavoprotein
composed of two identical 57-kDa subunits. The selenocysteine
residue is located at the penultimate COOH-terminal position
of TR, is encoded by a UGA codon (15–17), and is essential for
enzyme activity (6, 18). TR is a member of the pyridine nucle-
otide-disulfide oxidoreductase family of enzymes, but other
members of this family lack the COOH-terminal extension
containing the selenocysteine residue (15, 16). The reactivity of
TR with various alkylating agents, quinones, and gold-contain-
ing organic compounds is about 3 orders of magnitude greater
than that of these other enzymes (for example, glutathione
reductase and lipoamide dehydrogenase) (5, 7, 19). The inac-
tivation of TR by such compounds has been attributed to
the irreversible modification of the selenocysteine residue
(6, 7, 18, 19).
Structurally, selenocysteine differs from cysteine by the sin-
gle substitution of selenium for sulfur. Selenium is a better
nucleophile than sulfur and, under physiological conditions,
selenocysteine residues are ionized whereas cysteines are typ-
ically protonated (20, 21). These properties render selenocys-
teine a promising candidate for an ROS sensor in proteins.
Indeed, several selenoproteins (including TR) and selenium
compounds exhibit affinity for hydroperoxides and oxygen
radicals (22–24).
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We have tested whether selenocysteine in mammalian thi-
oredoxin reductase may be involved in redox regulation of cell
signaling. We initially identified two new thioredoxin reducta-
ses, TR2 and TR3, and found that all three mammalian thiore-
doxin reductases conserve the COOH-terminal penultimate
selenocysteine residue. We further found that, when cells gen-
erated ROS, selenocysteine in TR1 was oxidized while TR1
expression was elevated. The data suggest that the selenocys-
teine residue in thioredoxin reductases serves as a cellular
redox sensor.
EXPERIMENTAL PROCEDURES
Materials—Recombinant human thioredoxin was obtained from
American Diagnostica; recombinant Escherichia coli thioredoxin, hy-
drogen peroxide, 1-chloro-2,4-dinitrobenzene (DNCB) and NADPH from
Sigma; 5-IAF and anti-fluorescein antibodies from Molecular Probes;
pre-cast NuPAGE polyacrylamide gels and immunoblot system from
Novex; ADP-Sepharose, phenyl-Sepharose, and DEAE-Sepharose from
Amersham Pharmacia Biotech; C18 and phenyl-high performance liquid
chromatography (HPLC) columns from TosoHaas; mouse and human
expressed sequence tag clones for TR1, TR2, and TR3 from Research
Genetics, Genome Systems, and ATCC; mouse tissues from Pel-Freez;
and mouse multiple tissue Northern blot from CLONTECH. Other
reagents were of the highest grade available.
Isolation of TR1, TR2, and TR3—To obtain 75Se-labeled tissues, we
injected mice with 0.2 mCi of [75Se]selenite (specific radioactivity 1000
Ci/mmol; University of Missouri Research Reactor) 2 days before tissue
removal as described (25). Thioredoxin reductases were purified from
75Se-labeled mouse liver and testis according to the previously pub-
lished procedure (16), which consisted of the subsequent anion-ex-
change (DEAE-Sepharose), affinity (ADP-Sepharose), and hydrophobic-in-
teraction (phenyl-Sepharose or phenyl-HPLC column) chromatographic
procedures. To distinguish between TR isozymes, we assumed that, on the
basis of the deduced protein sequences, TR3 is more basic than is either TR1
or TR2, and that the molecular mass of TR2 is higher than that of TR1 or
TR3. Indeed, during purification, TR1, TR2, and TR3 had different affinities
for DEAE-Sepharose and phenyl-Sepharose columns. Purification yielded
homogenous preparations of 75Se-labeled liver TR1, testis TR1, testis TR2,
and liver TR3. The enzymes were detected during purification by their TR
catalytic activities as described by Tamura and Stadtman (17), by the pres-
ence of 75Se in fractions analyzed with a 5-detector Wallac g-counter and by
immunoblot assays. Rabbit antibodies specific for TR1 were generated
against two keyhole limpet hemocyanin-conjugated peptides corresponding
to residues 383–400 and 486–499 of human TR1, with the exception that
selenocysteine 498 and cysteine 497 were replaced with serines. Rabbit
antibodies specific for TR2 were generated in response to a keyhole limpet
hemocyanin-conjugated peptide corresponding to residues 560–579 of hu-
man TR2, with the exception that selenocysteine was replaced with cysteine.
Chicken antibodies specific for TR3 were generated in response to a keyhole
limpet hemocyanin-conjugated peptide corresponding to residues 502–520
of human TR3.
Alkylation of TR1 with 5-IAF—The procedure for alkylation by 5-IAF
of highly reactive, ROS-sensitive thiol or selenol groups in cell extracts
was adapted from Wu et al. (26). Nearly confluent A431 cells were
incubated for 16 h in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 0.1% fetal bovine serum (FBS), washed once with
DMEM containing 0.1% FBS, and then incubated either for 0–45 min
with EGF (500 ng/ml) in the same medium (Fig. 3C) or for 4 h in the
same medium containing 100 mCi of [75Se]selenite (Fig. 3D). The cells
were washed four times with phosphate-buffered saline and frozen in
liquid nitrogen. They were subsequently harvested at 4 °C by scraping,
under anaerobic conditions, into an oxygen-free lysis buffer containing
50 mM Tris-HCl (pH 7.5), leupeptin (2 mg/ml), aprotinin (2 mg/ml), 0.1
mM 4-(2-aminoethyl)benzenesulfonyl fluoride, 1% Nonidet P-40 deter-
gent, and 0.04% NaN3. Freshly prepared 5-IAF was added to a final
concentration of 20 mM before scraping. The cell lysate was incubated
under anaerobic conditions at 37 °C for 20 min, after which the alkyla-
tion reaction was quenched by the addition of 1 mM dithiothreitol.
After reaction with 5-IAF, the cell lysate was dialyzed against a
solution containing 25 mM Tris-HCl (pH 7.5), leupeptin (2 mg/ml), and
aprotinin (2 mg/ml), and TR1 was isolated from the dialysate by chro-
matography on ADP-Sepharose and DEAE-Sepharose columns. The
purified enzyme was characterized by SDS-PAGE, PhosphorImager
analysis of 75Se, and immunoblot analysis with antibodies to TR1 or to
fluorescein. The 5-IAF-modified enzyme (50 mg) was then further re-
duced with dithiothreitol in the presence of guanidine HCl, reacted with
iodoacetamide, and digested with trypsin, and the resulting peptides
were separated by reversed-phase HPLC on a C18 narrow-bore column
with a gradient of acetonitrile as described previously (16). The protein
mixture contained in the ADP-Sepharose flow-through fraction, which
was obtained during TR1 purification, was also digested with trypsin in
parallel with TR1, and the resulting peptides were separated on a C18
column under conditions identical to those used for fractionation of the
TR1 tryptic digest. This TR1-deficient sample served as a control for the
TR1 sample. The eluted peptides from the TR1 sample (Fig. 3D) and the
TR1-deficient sample were detected by measurement of absorbance at
214 and 440 nm; absorbance at the latter wavelength was used to
identify fluorescein-containing peptides. Only one major fluorescein-
containing peak (fractions 56 and 57) was detected for the TR1 tryptic
digest. This peak was not present in the fractions obtained from the
control digest of the TR1-deficient sample, whereas several smaller
peaks of absorbance at 440 nm present in the TR1 digest (Fig. 3D) were
also apparent in the digest of the TR1-deficient sample. Fractions from
the TR1 sample were analyzed for the presence of 75Se with a g-counter,
and two peaks containing 75Se were detected (Fig. 3D). The fractions
containing 75Se (39 and 56) were subjected to electrospray tandem
mass-spectrometric analysis, which detected the COOH-terminal pep-
tide in fraction 39 and the 5-IAF-labeled COOH-terminal peptide in
fraction 56.
Regulation of TR1 Expression—A431 cells were cultured in the pres-
ence of 10% FBS to near-confluence and then incubated in DMEM
containing 0.1% FBS for 16 h. The serum-deprived cells were washed
once with DMEM containing 0.1% FBS, and then incubated for 4 h in
DMEM containing 0.1% FBS and 20 mCi of [75Se]selenite, and in the
absence (control) or presence of either EGF (500 ng/ml), 0.2 mM H2O2,
or 10–30 mM DNCB. Cells were then washed four times with phosphate-
buffered saline and harvested by scraping in a lysis buffer containing 50
mM Tris-HCl (pH 7.5), leupeptin (2 mg/ml), aprotinin (2 mg/ml), 0.1 mM
4-(2-aminoethyl)benzenesulfonyl fluoride, sodium vanadate (2 mg/ml),
1% Nonidet P-40, and 0.04% NaN3. The cells were sonicated and the
resulting lysate was centrifuged at 15,000 3 g for 30 min, after which
the supernatant (3 mg of protein) was subjected to SDS-PAGE and
either immunoblot analysis with antibodies specific for TR1 or Phos-
phorImager analysis.
RESULTS AND DISCUSSION
Conservation of Selenocysteine in Mammalian Thioredoxin
Reductases—Only one mammalian TR isoform (TR1) has been
identified to date (15). We searched the human and mouse
dbEST data bases with human and rat TR1 sequences and
found several homologous human and mouse sequences. We
determined the sequences of the corresponding cDNAs by nu-
cleotide sequencing of expressed sequence tag clones, and iden-
tified two new TRs (TR2 and TR3) in humans and mice (Fig. 1,
A and B). The deduced sequences of the three TR isozymes
share .50% identity and show conservation of all functional
motifs, including two active-site redox cysteines in the NH2-
terminal region, the NADPH- and FAD-binding residues, and a
dimer interface domain (Fig. 1, A and B). The 39-untranslated
region sequences of all human and mouse TR isozyme mRNAs
contain selenocysteine insertion sequence elements (data not
shown) that are characteristic of all mammalian selenoproteins
(27). The TR isozymes are predicted to contain a selenocysteine
residue encoded by UGA in a conserved COOH-terminal GCUG
sequence (U, selenocysteine) (Fig. 1, B and C). For human
proteins, TR3 displays 52–53% identity with either TR1 or
TR2, while the latter two proteins are 70% identical. This
suggests a closer evolutional link between TR1 and TR2, while
TR3 is more distantly related to TR1 and TR2.
Computer search analysis of the non-redundant data base
with the human cDNA sequence revealed matches to the pre-
viously determined genomic DNA sequences (accession num-
bers AC000078, AC000080, AC000090) and the complete hu-
man TR3 gene sequence was derived from these sequences. The
human TR3 gene spans ;65 kilobases in the DiGeorge region
on chromosome 22q11.2 and has an unusual gene structure.
The 59-end of this gene, including 59-untranslated region and
Redox Signaling and Thioredoxin Reductases 24523
FIG. 1. Primary structures of mammalian TR isozymes. A, schematic representation of the domain organization of TR1, TR2, TR3, and
glutathione reductase (GR). These four proteins possess active center disulfides, FAD (flavin adenine dinucleotide)- and NADPH (reduced form of
nicotinamide adenine dinucleotide phosphate)-binding domains, and other features of the pyridine nucleotide-disulfide oxidoreductase family. TR1,
TR2, and TR3 also possess a COOH-terminal extension containing a conserved GCUG tetrapeptide sequence. TR3 contains a short NH2-terminal
extension with a putative mitochondrial-targeting signal. TR2 contains a long NH2-terminal extension. B, alignment of the deduced amino acid
sequences of human TR1 (hTR1) (GenBank accession no. S79851), mouse TR1 (mTR1, partial), hTR2 (partial), mTR2 (partial), hTR3, and mTR3
sequences. Residues conserved between corresponding human and mouse isozymes are highlighted in light gray, and those conserved among all
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the beginning of the open reading frame, overlaps in different
orientations with the 59-untranslated region of the membrane-
bound catechol O-methyltransferase gene (data not shown).
The physiological significance of this overlap and the possible
relevance of TR3 to DiGeorge syndrome will require further
studies.
FIG. 2. Characterization of TR1, TR2, and TR3. A, abundance of TR1, TR2, and TR3 mRNAs in various mouse tissues. A mouse
multiple-tissue Northern blot (CLONTECH) was developed with cDNA probes specific for mouse TR1, TR2, TR3, and actin mRNAs. The sizes of
transcripts (in kilobases) are shown on the right. B, abundance of TR1 and TR2 proteins in various mouse tissues. 75Se-labeled proteins in mouse
tissues were separated by SDS-PAGE and detected by PhosphorImager (Molecular Dynamics) analysis. TR3 is less abundant than TR1 and is not
apparent in this figure. The 75Se band that appears in the liver sample slightly above the position of testis TR2 is most likely not TR2. The positions
of glutathione peroxidases GPX1 and GPX4 and of the 15-kDa selenoprotein (which are the other major cellular selenoproteins), in addition to those
of TR1 and TR2, are indicated. C, characterization of purified preparations of mouse liver TR1, testis TR2, and liver TR3. The purified proteins
were subjected to SDS-PAGE and immunoblot analysis with antibodies specific for TR1 (top panel), for TR2 (second panel), or for TR3 (third panel);
75Se detection (for 75Se-labeled proteins) by PhosphorImager analysis (fourth panel); or Coomassie Blue staining (bottom panel). The 75Se-labeled
band for TR2 is not clearly visible because the protein was isolated from testis with a low 75Se specific radioactivity. The positions of TR2 and of
TR1 and TR3 are indicated on the right. It is not clear why TR1 mRNA is barely detectable in testis (see A), when the level of the corresponding
protein is high in this tissue (see B). It should be noted that the Northern blots were carried out on a commercial filter that had been stripped and
rehybridized several times and that the strains of mice used for mRNA and protein analysis were different.
mammalian TR isozymes are highlighted in dark gray. Sequences of internal tryptic peptides indicated by boxes were experimentally verified by
tandem mass-spectrometry (hTR1 and mTR3) or Edman degradation (mTR1, mTR2, and mTR3). The putative NH2-terminal mitochondrial signal
in hTR3 and mTR3 is underlined. Residue numbers for each protein are shown on the right. C, alignment of the COOH-terminal sequences of
mammalian and C. elegans TR enzymes. Human glutathione reductase, which is highly homologous to TR but lacks the COOH-terminal extension,
is shown for comparison. Selenocysteine is replaced with cysteine in one form of C. elegans TR. Residues conserved among all TRs are shaded.
GenBank accession numbers are indicated on the right. U, selenocysteine.
Redox Signaling and Thioredoxin Reductases 24525
FIG. 3. Role of TR1 in redox regulation of cell signaling. A, alkylation of NADPH-reduced, but not of oxidized, TR1 by 5-IAF. NADPH-
reduced or oxidized TR1 was incubated for 10 min at 25 °C in the presence or absence of 20 mM 5-IAF, and was then subjected to immunoblot
analysis with antibodies to TR1 (upper panel) or to fluorescein (lower panel). B, oxidation by hydrogen peroxide of NADPH-reduced TR1 in vitro.
75Se-Labeled TR1 was reduced for 10 min with 100 mM NADPH, oxidized for 10 min with the indicated concentration of H2O2, and then incubated
for 10 min with 20 mM 5-IAF. The protein was then subjected to SDS-PAGE and either immunoblot analysis with antibodies specific for TR1 (top
panel) or for fluorescein (bottom panel), or to PhosphorImager analysis of 75Se (middle panel). C, effect of stimulation of A431 cells with EGF on
the redox state of TR1 in vivo. Serum-deprived A431 cells were incubated with EGF (500 ng/ml) for the indicated times, after which cell lysates
were prepared under anaerobic conditions and incubated for 20 min with 20 mM 5-IAF. TR1 was then isolated from reacted cell lysates using
ADP-Sepharose and analyzed by immunoblot assay with antibodies to either TR1 or fluorescein. D, co-elution of 75Se-labeled and 5-IAF-targeted
tryptic peptides of TR1. A431 cells were incubated with [75Se]selenite for 4 h, after which cell lysates were prepared under anaerobic conditions
and exposed for 20 min to 20 mM 5-IAF. TR1 was then isolated from the lysates and digested with trypsin, and the resulting peptides were
fractionated by reversed-phase HPLC. Absorbance at 214 nm (upper panel) and 440 nm (middle panel) was used to detect peptides and fluorescein,
respectively. The lower panel shows the 75Se radioactivity profile. E, specific alkylation of selenocysteine in TR1 by 5-IAF. Fraction 56 from D,
containing both 75Se and fluorescein, was subjected to mass spectrometry analysis to determine the mass of the peptide, followed by amino acid
sequencing by tandem mass spectrometry. The experimentally determined mass for the 5-IAF-labeled peptide in fraction 56, [M 1 2H]21 5 779.73,
matched the predicted mass for the COOH-terminal tryptic peptide of TR1 that is modified with a single 5-IAF group (shown as circled F) and a
single iodoacetamide group (shown as circled A), [M 1 2H]21 5 779.48. This double-charged ion was completely fragmented and is not seen in this
figure. yn and bn are the ions in which amino acid residues are sequentially cleaved from the NH2-terminal and COOH-terminal, respectively.
Importantly, the y2 ion defines the selenocysteine-glycine COOH-terminal dipeptide modified with 5-IAF, and the b10 ion defines the SGAS-
ILQAGC peptide containing cysteine that is not modified with 5-IAF. Neither the corresponding y2 ion containing unmodified selenocysteine nor
b10 ion containing a 5-IAF-modified cysteine were detected. This suggests that selenocysteine was modified, but cysteine was not, with 5-IAF. The
predicted molecular masses for fragment ions of types b and y are shown under the sequence, and ions observed in the spectrum are underlined.
m/z, mass/charge ratio. F, effects of stimulation of A431 cells with EGF or H2O2 on the expression of TR1. Cells were incubated for 4 h in the absence
(control) or presence of EGF (500 ng/ml) or 0.2 mM H2O2, after which cell lysates were subjected to immunoblot analysis with antibodies to TR1
or to thioredoxin (Trx). G, effects of stimulation of A431 cells with EGF or H2O2 on the abundance of
75Se-labeled TR1, GPX1, and GPX4. Cells were
labeled with [75Se]selenite in the absence (control) or presence of EGF (500 ng/ml) or 0.2 mM H2O2 for 4 h, after which cell lysates were subjected
to SDS-PAGE and PhosphorImager analysis of 75Se-labeled proteins. TR3 is less abundant than TR1 and is not apparent on this figure. H, effect
of DNCB on the intracellular abundance of TR1. A431 cells were incubated for 4 h with [75Se]selenite and the indicated concentrations of DNCB,
after which cell lysates were subjected to SDS-PAGE and PhosphorImager analysis of 75Se-labeled proteins.
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Northern (RNA) hybridization and analysis of 75Se-labeled
mouse proteins suggested that TR1 and TR3 are expressed in a
variety of tissues, being especially abundant in liver, whereas
TR2 is preferentially expressed in testis (Fig. 2, A and B). We
therefore directly purified to homogeneity, from 75Se-labeled
mouse tissues, TR1 from mouse liver and testis, TR2 from
mouse testis, and TR3 from mouse liver (Fig. 2C). The identi-
ties of all TR isozymes were confirmed by immunoblot analysis
with isozyme-specific antibodies to TR1, TR2, and TR3, and by
comparison of the sequences of tryptic peptides with the pre-
dicted TR1, TR2, and TR3 amino acid sequences (Fig. 1B). In
contrast to TR1 and TR3 which migrated as ;57-kDa species
on SDS-PAGE gels, TR2 had a higher, ;65-kDa, molecular
mass (Fig. 2C) that is consistent with the coding region derived
from the cDNA sequence.
TR1 exists in the cytoplasm (28). TR3 has a putative mito-
chondrial signal (the enrichment of arginines in the NH2-ter-
minal structure that forms an a-helix) (Fig. 1, A and B), sug-
gesting that it may be a mitochondrial enzyme. The
experimentally determined NH2-terminal sequence of mouse
FIG. 3.—continued
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liver TR3 is GGQQSFDLLV, indicating the post-translational
processing of first 34 residues. This processing is consistent
with the apparently similar mobility of mouse liver TR1 and
TR3 on SDS-PAGE gels. Thioredoxin reductase has recently
been isolated from mitochondria, and the properties of the
enzyme are different from those of TR1 (29). It is possible that
three mammalian TRs have related functions in different cel-
lular compartments.
Redox Regulation of Cell Signaling by Selenocysteine in
TR1—On the basis of the redox properties of the selenocysteine
in TR1 (5–7, 9, 18, 19, 22, 23) and on the basis of conservation
of selenocysteine in mammalian TRs, we investigated whether
oxidation of selenocysteine in TR isozymes by ROS might con-
tribute to redox signaling. Specifically, we examined the effect
of ROS on the redox state of TR1, which we monitored by
alkylating thiol and selenol groups in the enzyme with 5-IAF
and subsequently detecting fluorescein-modified protein by im-
munoblot analysis (26). We initially confirmed that purified
mouse liver TR1 did not react with 5-IAF, whereas the
NADPH-reduced form of the enzyme was alkylated by this
compound (Fig. 3A). Thus, changes in the fluorescein content of
5-IAF-treated TR1 reflect the redox state of the enzyme.
With this approach, we further tested whether incubation of
NADPH-reduced TR1 with hydrogen peroxide leads to oxida-
tion of the enzyme. In the presence of 5-IAF, oxidation of the
enzyme would be reflected by the decreased level of fluorescein
in immunoblots with anti-fluorescein antibodies. We found that
an increasing concentration of hydrogen peroxide from 0 to 500
mM indeed results in lowering the fluorescein signal (Fig. 3B,
bottom panel), while not affecting the protein level (Fig. 3B,
upper panel) or the amount of 75Se present in the protein (Fig.
3B, middle panel). This suggests that hydrogen peroxide oxi-
dized the thiol and/or selenol groups in the enzyme in the
presence of NADPH.
To assess intracellular changes in the redox state of TR1, we
used human epidermoid carcinoma A431 cells, which generate
ROS (predominantly, hydrogen peroxide) in response to stim-
ulation with EGF (10). In these cells, ROS induce tyrosine
phosphorylation of proteins as a result of initial oxidation and
subsequent thioredoxin-dependent reduction of PTP1B (13).
The analogous reversible changes in the redox status of pro-
tein-disulfide isomerase, a thioredoxin homolog and substrate
for TR1, also occur in EGF-stimulated cells (30). Exposure of
A431 cells to EGF for up to 45 min resulted in a time-dependent
oxidation of TR1 (Fig. 3C), indicating that oxidation of one or
more thiol or selenol groups in TR1 occurs in response to the
generation of ROS in EGF-treated cells. This is consistent with
previous observation of oxidation of the 55-kDa protein, which
was suggested to be thioredoxin reductase (30).
To identify the TR1 residues oxidized by ROS intracellularly,
we metabolically labeled A431 cells with 75Se, incubated the
labeled cell lysate with 5-IAF, and then isolated TR1. The
purified 5-IAF-modified TR1 was then subjected to further
alkylation with iodoacetamide (to protect previously unmodi-
fied thiol or selenol groups) followed by digestion with trypsin,
after which the resulting peptides were separated by reversed-
phase HPLC. Analysis of fluorescein and 75Se in the column
fractions revealed the presence of two 75Se-containing peptides
but only one fluorescein-containing peptide (Fig. 3D), the latter
of which co-eluted with the second 75Se-containing peptide.
Sequence analysis by tandem mass-spectrometry identified the
COOH-terminal selenocysteine-containing tryptic peptide in
both fractions containing 75Se. Only the second eluted COOH-
terminal tryptic peptide contained a fluorescein moiety, and
the only site of modification was the selenocysteine residue
(Fig. 3E). These observations indicated that the selenol group
in TR1 is the only site of modification by 5-IAF, suggesting that
selenocysteine is the only residue of TR1 oxidized by ROS in
A431 cells.
Prolonged (4 h) incubation of A431 cells with EGF resulted in
an ;5-fold increase in the intracellular abundance of TR1, as
revealed by immunoblot analysis (Fig. 3F). The amount of TR1
was also increased as a result of incubation of A431 cells with
hydrogen peroxide. The TR1 present in cells after prolonged
stimulation of cells with EGF or H2O2 is most likely in a
reduced state, given that EGF- or H2O2-stimulated cells exhibit
a transient (,30 min) increase in ROS (10) and a corresponding
transient (,1 h) oxidation of PTP1B (13) and protein-disulfide
isomerase (30). The abundance of thioredoxin, the substrate of
TR1, was not affected by prolonged incubation of A431 cells
with either EGF or H2O2 (Fig. 3F).
The increase in the intracellular abundance of TR1 induced
by prolonged incubation of cells with EGF or H2O2 was also
apparent by labeling the cells with 75Se and subsequent detec-
tion of labeled proteins by SDS-PAGE (Fig. 3G). The latter
approach (25, 31) also detected other major antioxidant Se-
containing enzymes revealing that the intracellular concentra-
tions of cytosolic glutathione peroxidase (GPX1) and phospho-
FIG. 4. Model for the role of TR in
redox regulation of cell signaling.
Trx, thioredoxin; RR, ribonucleotide re-
ductase; Tpx, thioredoxin peroxidase;
MAPK, mitogen-activated protein kinase;
PTP, protein-tyrosine phosphatase. See
text for details.
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lipid hydroperoxide glutathione peroxidase (GPX4) were not
substantially affected by stimulation of cells with EGF or H2O2.
Incubation of A431 cells with DNCB mimicked the effect of
EGF in that it increased the expression of TR1 but not that of
GPX1, GPX4, and the recently discovered 15-kDa selenoprotein
(32) (Fig. 3H). DNCB specifically inhibits TR1 through irre-
versible modification of the selenocysteine residue (8). Incuba-
tion of 293 cells with 20 mM DNCB for 30 min induces activation
of ASK1 through oxidation of the thioredoxin system, and TR1
inactivation by DNCB has been implicated as a critical trigger
for this process (12). Thus, ROS and DNCB, which possess
distinct chemical properties, both target selenocysteine in TR1
and appear to induce oxidation of the thioredoxin system and a
subsequent increase in the expression of TR1. These data are
also consistent with a mechanism in which the intracellular
ROS pathway is regulated through the selenocysteine residue
in TR1, rather than through effects on thioredoxin or glutathi-
one peroxidases.
Our results suggest a model for the role of TR in redox-
regulated cell signaling (Fig. 4). The intracellular generation of
ROS results in the direct oxidation of the selenol group of TR
(shown as a solid arrow in Fig. 4) and a consequent transient
decrease in enzyme activity. The resulting oxidation of thiore-
doxin then affects thioredoxin-dependent cellular components,
including transcription factors (such as nuclear factor kB (NF-
kB)) (33), protein-tyrosine phosphatases (such as PTP1B), and
antioxidant enzymes (such as thioredoxin peroxidase). In ad-
dition, ROS may directly target other proteins such as thiore-
doxin, phosphatases, and kinases with variable efficacy (shown
as dashed arrows in Fig. 4). The system is recycled as a result
of the subsequent increased expression of TR, and possibly
through the NADPH-dependent reduction of the enzyme after
removal of the ROS by antioxidant enzymes.
Additional characteristics of TR1 support a critical role for
this protein in redox signal transduction. Thus, TR1 is coupled
with Ca21-phosphoinositide signaling pathways (34), and it
exhibits oncoprotein-like properties (35). Oncogene products
often regulate cell growth by simultaneously promoting cell
proliferation and sensitizing cells to apoptosis (36), both of
which effects have been demonstrated for TR1 and thioredoxin
(37–42). Furthermore, Caenorhabditis elegans contains two TR
genes (Fig. 1C), one of which encodes a selenocysteine-contain-
ing enzyme that is the major, if not the only, selenoprotein in C.
elegans (43), whereas the other encodes a protein with cysteine
in place of selenocysteine. In contrast, the bacterial-type TR
enzymes (also present in plants and yeast) show limited homol-
ogy to animal TRs (5, 15) and lack the COOH-terminal seleno-
cysteine-containing extension, suggesting a different role for
TR in redox regulation in bacteria. The well-characterized bac-
terial redox signaling protein OxyR, a transcription factor, is
directly activated by H2O2 and is inhibited by glutaredoxin
through the thiol-disulfide exchange process (44).
Concluding Remarks—Our demonstration that the seleno-
cysteine residue of TR1 senses the presence of ROS might
explain the location of this residue at the penultimate position
of the COOH terminus of the protein. Consistent with its sen-
sory role, selenocysteine is conserved in the newly discovered
TR2 and TR3. Selenocysteine is generally more reactive than
cysteine as a result of the ionization and redox properties of
selenium (20, 21). In addition to TRs, only 11 other mammalian
selenoproteins are known (20, 21, 45). Removal of either sel-
enocysteine tRNA or thioredoxin genes from the mouse genome
results in embryonic death (46, 47). Finally, whereas the TR-
thioredoxin system is important in signaling by ROS, a role of
the glutathione system in signaling remains to be demon-
strated. Thus, the former rather than the latter is possibly the
major cellular redox signaling system.
Addendum—When this manuscript was ready for submission, two
papers were published that describe the cloning and characterization of
rat TrxR2 (48) and human TRb (49). Based on sequences, these proteins
are apparently the same proteins as TR3. From our study, TR1 and TR2
sequences are evolutionally more related to each other than to TR3.
Therefore, we suggest naming the three thioredoxin reductases as pre-
sented in this paper.
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